Mersana Therapeutics enters $100M ATM sales agreement with TD Cowen

Mersana Therapeutics, Inc.

Company entered Sales Agreement to sell up to $100M of common stock at-the-market through TD Cowen.
TD Cowen will receive up to 3.0% commission per share sold; no minimum obligation to sell shares.
Offering is under existing S-3 registration statement that became effective February 28, 2024.
Company may suspend or terminate the offering at any time upon notice to TD Cowen.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Mersana Therapeutics, Inc. entered into Sales Agreement with Cowen and Company, LLC valued at up to $100,000,000 (effective 2024-02-28).

Action: entry
Agreement: atm program
Counterparty: Cowen and Company, LLC
Value: up to $100,000,000
Effective: 2024-02-28

Exact text from the filing

On February 28, 2024, Mersana Therapeutics, Inc., a Delaware corporation (the “Company”), entered into a Sales Agreement (the “Sales Agreement”) with Cowen and Company, LLC as agent (“TD Cowen”) pursuant to which the Company may issue and sell shares of its common stock, $0.0001 par value per share, having an aggregate offering price of up to $100,000,000

View on SEC.gov

754 material agreements filed in the last 30 days. Browse all material agreements →

Source: SEC EDGAR

accession 0001104659-24-028715

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.